News on Neoplasms_Multiple_Primary from BioPortfolio.com http://www.BioPortfolio.com Consolidated Neoplasms_Multiple_Primary news from BioPortfolio.com Wed, 10 Feb 2010 16:36:33 GMT en Multiple Primary Malignant Neoplasms Associated with Prostate Cancer in 312 Consecutive Caseshttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023781&HITNO=0&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023781&THISHREF=http://c.moreover.com/click/here.pl%3fz2528397519%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4023781&HITNO=0&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4023781&THISHREF=http://c.moreover.com/click/here.pl%3fz2528397519%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comUrologia Internationalis: Spectrum and Topotargethttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999463&HITNO=1&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999463&THISHREF=http://c.moreover.com/click/here.pl%3fz2517449323%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999463&HITNO=1&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999463&THISHREF=http://c.moreover.com/click/here.pl%3fz2517449323%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioFind: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4000314&HITNO=2&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4000314&THISHREF=http://c.moreover.com/click/here.pl%3fz2517960158%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4000314&HITNO=2&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4000314&THISHREF=http://c.moreover.com/click/here.pl%3fz2517960158%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharma Live: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4000013&HITNO=3&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4000013&THISHREF=http://c.moreover.com/click/here.pl%3fz2517784705%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=4000013&HITNO=3&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=4000013&THISHREF=http://c.moreover.com/click/here.pl%3fz2517784705%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comPharmacy Choice: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996846&HITNO=4&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996846&THISHREF=http://c.moreover.com/click/here.pl%3fz2516487524%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996846&HITNO=4&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996846&THISHREF=http://c.moreover.com/click/here.pl%3fz2516487524%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire UK: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996804&HITNO=5&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996804&THISHREF=http://c.moreover.com/click/here.pl%3fz2516473437%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996804&HITNO=5&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996804&THISHREF=http://c.moreover.com/click/here.pl%3fz2516473437%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comStockwatch: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996803&HITNO=6&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996803&THISHREF=http://c.moreover.com/click/here.pl%3fz2516473372%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996803&HITNO=6&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996803&THISHREF=http://c.moreover.com/click/here.pl%3fz2516473372%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBusiness Wire: Spectrum Pharmaceuticals, Inc. (SPPI) Licenses Belinostat from TopoTarget A/S for $http://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999767&HITNO=7&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999767&THISHREF=http://c.moreover.com/click/here.pl%3fz2517637986%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3999767&HITNO=7&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3999767&THISHREF=http://c.moreover.com/click/here.pl%3fz2517637986%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBioSpace: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997297&HITNO=8&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997297&THISHREF=http://c.moreover.com/click/here.pl%3fz2516636967%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997297&HITNO=8&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997297&THISHREF=http://c.moreover.com/click/here.pl%3fz2516636967%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997269&HITNO=9&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997269&THISHREF=http://c.moreover.com/click/here.pl%3fz2516622611%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997269&HITNO=9&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997269&THISHREF=http://c.moreover.com/click/here.pl%3fz2516622611%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotalhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997014&HITNO=10&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997014&THISHREF=http://c.moreover.com/click/here.pl%3fz2516537416%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3997014&HITNO=10&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3997014&THISHREF=http://c.moreover.com/click/here.pl%3fz2516537416%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comForbes.com: Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trialhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996857&HITNO=11&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996857&THISHREF=http://c.moreover.com/click/here.pl%3fz2516491605%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3996857&HITNO=11&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3996857&THISHREF=http://c.moreover.com/click/here.pl%3fz2516491605%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comRBC Dain Rauscher: Geographic Information Systems (GIS) Demonstrating Primary Care Needs for a Transitioning Hispanic Communityhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3906859&HITNO=12&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3906859&THISHREF=http://c.moreover.com/click/here.pl%3fz2467191193%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3906859&HITNO=12&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3906859&THISHREF=http://c.moreover.com/click/here.pl%3fz2467191193%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comMDLinx: Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005 02) Evaluating Treatment with Continuous REVLIMID(R) in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3896733&HITNO=13&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3896733&THISHREF=http://c.moreover.com/click/here.pl%3fz2461899604%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3896733&HITNO=13&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3896733&THISHREF=http://c.moreover.com/click/here.pl%3fz2461899604%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFOXBusiness.com: Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005 02) Evaluating Treatment with Continuous REVLIMID in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Meets Primary Endpointhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3896626&HITNO=14&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3896626&THISHREF=http://c.moreover.com/click/here.pl%3fz2461851492%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3896626&HITNO=14&MSIZE=18&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=Neoplasms_Multiple_Primary&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R:date&R=3896626&THISHREF=http://c.moreover.com/click/here.pl%3fz2461851492%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comFinancial 24: